Medtronic gives $3.75m helping hand to NanoCor:
This article was originally published in Clinica
Executive Summary
Medtronic has invested $3.75m in gene therapy start-up NanoCor Therapeutics to allow the latter to develop a treatment for congestive heart failure (CHF). NanoCor is aiming to use a genetically-engineered virus, developed using NanoCor-affiliate AskBio's Biological NanoParticle and self-complementary vector technologies, as a way of delivering drugs to failing heart muscles. If preclinical tests of the technology are successful, Medtronic has agreed to invest a further $3.75m. In return, Medtronic gains certain exclusive rights to licence the therapeutic, and rights to develop AskBio's technologies for the treatment of diseases of the central nervous system. Chapel Hill, North Carolina-based NanoCor will also use the new capital to hire six employees to join sole member of staff CEO Sheila Mikhail.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.